PATTERNOX LTD developed an innovative imaging method of Lateral Movements of Backscattered-light (LMB), capable of extracting tissue distortions that do not rely on the ubiquitous color change but on distortions occurring below the skin surface. The imaging reveals early indicators, well before it progresses into a skin cancer or cosmetic concern.
ofir@patternox.com , WhatsApp: +972-526164669

Accomplished to date
✔ 2024 we were awarded a prize for innovation in a TV contest based on the Shark Tank show.
✔ 2023, The  Israel Innovation Authority (IIA) chose us to participate in the Singapore-Israeli delegation.
✔ 2022, We passed the scrutinization of Josseph Sassoon Group for future potential investment.
✔ 2021, Won a contest by Vision-Elements (AI).

✔ Clinical trial, more than 10,000 measurements.
✔ Regulatory strategy. GSAP.
✔ Patent, at a national stage (After PCT and IDS). 
✔ New PatScope Scanner (MVP, trl6).
✔ Business plan. Business model.
✔ Conference presentations.
✔ Proposal to Space Agency to investigate astronaut's skin degradation under microgravity conditions.

Market
Clinics and centers, Dermatologists, General practitioners (GPs), Beauticians, and home users. 

The TAM is greater than $1 billion USD, and growing rapidly with a CAGR > 10%.

We have attracted and are increasingly continuing to attract Clinics, worldwide.
​
Business model
Sales - of the scanner as standalone unit and as adapter for smartphones.
AI - for lesion distortion as decision support.
Telemedicine - our dermatologists will assist with follow-ups.
Reimbursement - following CPT code similar to x-ray, CT, and MRI.

Current activities
• We are in preliminary planning for the development of the next generation of the PatScope.
• Submitting a pre-submission to the FDA to confirm the regulatory pathway we built with Duet Medical and GSAP as control and re-examination. Design clinical trials according to the FDA's an

PATTERNOX

Org chart

Teams

Offices

PATTERNOX

Org chart

Teams

Offices

Related companies